Introduction
============

Nasopharyngeal carcinoma (NPC), which is endemic in South China, is the eighth most common cause of cancer-related mortality.[@b1-ott-12-1553] At initial diagnosis, the majority of patients (75%--90%) suffered with locoregionally advanced NPC.[@b2-ott-12-1553] The standard treatment for locoregionally advanced NPC is cisplatin (CDDP)-based chemoradiotherapy (CRT) according to randomized trials[@b3-ott-12-1553],[@b4-ott-12-1553] and meta-analyses.[@b5-ott-12-1553],[@b6-ott-12-1553]

Intensity modulated radiotherapy (IMRT), which yields more satisfactory outcomes than conventional radiotherapy (RT),[@b7-ott-12-1553],[@b8-ott-12-1553] delivers a higher radiation dose to the tumor tissues while limiting the dose to normal tissues in NPC patients. Although IMRT has greatly improved overall survival (OS) of NPC patients, more than 10% patients still faced with a high risk of developing distant metastasis after IMRT,[@b9-ott-12-1553] indicating IMRT was not sufficient for treatment of NPC patients.

Chemotherapy was important to control metastasis of NPC patients,[@b4-ott-12-1553] but the efficacy of concurrent CRT (CCRT) in combination with IMRT was controversial. Retrospective studies in patients with T4 NPC demonstrated that CCRT + IMRT failed to improve patients' OS, distant metastasis-free survival (DMFS), or progression-free survival (PFS) compared to IMRT.[@b10-ott-12-1553] In another study of stage II--IVb NPC patients, adding CCRT showed significant improvement of DFS.[@b11-ott-12-1553]

Although neoadjuvant chemotherapy (NACT) failed to improve OS in previous Phase III trials, certain Phase II studies have reported promising results.[@b12-ott-12-1553],[@b13-ott-12-1553] Hui et al reported that in the NACT group, patients' 3-year OS rate was 94.1%, which was significantly higher than that of the CDDP-based CRT group (67.7%).[@b14-ott-12-1553] A meta-analysis demonstrated that NACT resulted in OS gain of 5.13% and reduced the distant metastasis rate within 3 years with no significant reduction in the locoregional recurrence rate.[@b15-ott-12-1553] Therefore, the value of NACT in locoregionally advanced NPC remains controversial. Novel strategies are required to effectively improve patients' OS.

The effectiveness and safety of NACT regimen (GEM + CDDP/carboplatin) followed by CDDP-based CRT have been confirmed, which demonstrated that CDDP-based CRT induced high frequencies of hematologic toxicities and nausea/vomiting.[@b13-ott-12-1553] Nedaplatin (NDP), a platinum complex with a similar action mechanism but different molecular structure from CDDP, was evidenced to be at least as effective as CDDP in the treatment of locoregionally advanced NPC.[@b16-ott-12-1553] CCRT was regarded as standard therapeutic approach for locoregionally advanced NPC.[@b17-ott-12-1553]

The aim of the present retrospective study was to compare the efficacy of NACT regimen (GEM + NDP) + IMRT and NACT regimen (GEM + NDP) + IMRT + CCRT (NDP), to determine the necessity of CCRT following NACT in the era of IMRT.

Patients and methods
====================

Patient eligibility
-------------------

Between September, 2010 and December, 2014, 125 eligible NPC patients, who suffered from WHO type II (nonkeratinizing differentiated carcinoma) or type III (nonkeratinizing undifferentiated carcinoma) NPC[@b18-ott-12-1553] and stage III--IVB NPC (2010 American Joint Committee on Cancer \[AJCC\] staging system for NPC)[@b19-ott-12-1553] and whose Karnofsky Performance Scale score was ≥70 with no distant metastasis, adequate hepatic, renal or hematologic function, were treated at Zhejiang Cancer Hospital and participated in our study.

Prior inform and written consent was obtained from each patient. The current study was approved by the Ethics Committee of Zhejiang Cancer Hospital. The research was carried out in accordance with the Helsinki Declaration. Our report complies with all IRB requirements at the institution(s) where the work was performed.

Physical examination
--------------------

Initial evaluation, which was carried out before the treatment in NPC patients, included complete blood cell count, comprehensive serum chemistry profile, chest X-ray or computed tomography (CT), electrocardiogram, MRI scans of the nasopharynx and upper neck, nasopharyngoscopy, and liver ultrasonography.

Chemotherapy
------------

The NACT regimen was carried out as follows: NDP (25 mg/m^2^, day 1--3, 60 minutes, every 3 weeks) and GEM (1,000 mg/m^2^, day 1 and 5, 30 minutes, every 3 weeks). In case of low blood count or intolerable toxicity, which was resulted from the preceding chemotherapy cycle, the dosage would be modified accordingly. If the count of platelet, leukocyte, or red blood cell decreased to ≤25 × 10^9^/L, ≤1 × 10^9^/L or ≤50 × 10^9^/L, respectively, the dosage would decrease by 25% in the next cycle.

CCRT which was carried out as follows: NDP (25 mg/m^2^, day 1--3 at every 3 weeks, 60 minutes during IMRT) would be postponed even suspended when the grade 4 hematologic adverse events or intolerable toxicities arose.

RT
--

The gross tumor volume (GTV) was defined as the primary tumor (including lymph nodes). The planning target volume of the primary tumor (PTVg) was defined as the GTV of the tumor with a 0.3--0.5 cm margin, while the planning target volume of the metastatic nodes (PTVnd) was defined as the GTV of the nodes with a 0.3--0.5 cm margin. A total dose of 69 and 63 Gy over 6 weeks in 30 fractions was prescribed for PTVg and GTVnd, respectively.

The clinical target volume (CTV) was defined as the anterior third of the clivus, the entire nasopharyngeal cavity, parapharyngeal space, pterygoid plates, posterior third of the nasal cavity, maxillary sinus, inferior sphenoid sinus, and the drainage of the upper neck (levels II, III, and Va) in N0. Levels IV and Vb were defined as N1--3. PTVH was defined as the high-risk CTV with a 0.3--0.5 cm margin, while PTVL was defined as the low-risk CTV. A total dose of 60 and 54 Gy in 30 fractions was prescribed for PTVH and PTVL, respectively.

Patients received IMRT with 6 MV X-rays. All patients were irradiated with one fraction daily for 5 days/week.

The mean dose and maximum dose (in Gy) to crucial organ at risk, including brainstem, spinal cord, optic chiasm, left/right optic nerve, left/right temporal lobe, left/right parotic gland, and left/right temporomandibular joint, were exhibited in [Table 1](#t1-ott-12-1553){ref-type="table"}.

The dose--volume histogram statistics of targets, including PGTVnx, GTVnd, PTVnd, PTV1, and PTV2, are presented in [Table 2](#t2-ott-12-1553){ref-type="table"}.

The contouring of GTV was closely corresponding to the original diseased tissues in all dimensions when considering the imaging post NACT.[@b20-ott-12-1553]

Treatment response, follow-up, and adverse effects
--------------------------------------------------

Treatment-related toxicities were graded according to the National Cancer Institute Common Toxicity Criteria, version 3.0.[@b21-ott-12-1553]

PFS was estimated from the date of pathological diagnosis to the date of relapse or metastasis following the completion of all treatments. MFS and RFS were defined as the interval from the date of pathological diagnosis to the date of distant metastasis or relapse. OS was measured from the date of pathological diagnosis to the date of death or the last date when the patient was recorded alive. Prior to treatment and after RT within 3 months, a follow-up MRI of the nasopharynx and upper neck and intensive CT of chest and abdomen were carried out to evaluate responses based on the Response Evaluation Criteria in Solid Tumors criteria.[@b22-ott-12-1553]

After the completion of the treatments, patients were required to attend outpatient checkups every 3 months in the subsequent 2 years followed by attention of outpatient checkups every 6 months while the patients remained alive. Each follow-up included clinical examination, nasopharyngoscopy, MRI, intensive CT of the chest and abdomen, comprehensive serum chemistry profiles, and blood cell count. Other tests were performed at the discretion of the treating physician.

Statistical analysis
--------------------

Descriptive statistical analyses were applied to characterize the patients in NACT + IMRT and NACT + IMRT + CCRT groups. Chi-squared test, which was carried out with SPSS 19.0 software (IBM Corporation, Armonk, NY, USA), was adopted for the estimation of the differences in clinical characteristics (WHO histology, AJCC stage, T stage, N stage, histologic types, and course of NACT) and demographic variables (gender, age, alcohol use, smoking history, and family history). Survival rates were calculated by the Kaplan--Meier method. Univariate analysis with log-rank test and multivariate analysis by the Cox proportional hazard model were done to test the independent prognostic factors for patients' OS, DMFS, local relapse-free survival (LRFS), and PFS. Statistical significance was set at *P*\<0.05.

Results
=======

Patients
--------

Characteristics of NPC patients treated with NACT + IMRT or NACT + IMRT + CCRT were summarized and exhibited in [Table 3](#t3-ott-12-1553){ref-type="table"}. The median age of diagnosis was 55 years (17--77 years) in NPC patients. In total, 83 (66.4%) of the patients were male and 42 (33.6%) of the patients were female. There were 36 (28.8%) patients treated with NACT + IMRT and 89 (71.2%) patients treated with NACT + IMRT + CCRT. The patient distribution between the two different groups was well-balanced based on the prognostic factors, including the age of diagnosis (*P*=0.296), gender (*P*=0.429), smoking history (*P*=0.162), alcohol use (*P*=0.454), family history (*P*=0.525), WHO histology (*P*=0.603), AJCC stage (*P*=0.319), T stage (*P*=0.276), N stage (*P*=0.153), and courses of NACT (*P*=0.548).

Treatment-related toxicities
----------------------------

As shown in [Table 4](#t4-ott-12-1553){ref-type="table"}, no grade 5 toxicities were observed during NACT or RT. The frequency of grade 3--4 hematologic toxicities during NACT or RT in NACT + IMRT + CCRT group was lower than that in NACT + IMRT group. Regarding RT, 125 patients completed it.

Regarding NACT, 13 patients (10.4%) completed one cycle, 93 patients (74.4%) completed two cycles, 17 patients (13.6%) completed three cycles, and 2 patients (1.6%) completed four cycles. During NACT, six patients (4.8%) received 25% reduction of dose due to treatment-related toxicities; the most common grade 3--4 hematologic and nonhematologic toxicities were neutropenia (38, 30.4%), leukopenia (16, 12.8%), thrombocytopenia (16, 12.8%), and liver dysfunction (11, 8.8%).

Regarding CCRT, 20 patients (16.0%) completed one cycle, 69 patients (55.2%) completed two cycles, and 36 patients (28.8%) did not receive it. During CCRT, the most common grade 3--4 hematologic and nonhematologic toxicities were oropharyngeal mucositis (18, 14.4%), nausea/vomiting (15, 12.0%), thrombocytopenia (8, 6.4%), and anemia (7, 5.6%). Of the 36 patients who did not receive CCRT, eleven patients (30.5%) suffered grade 3--4 hematologic toxicities at the beginning of RT, nine patients (25%) suffered grade 3--4 hematologic toxicities during NACT, accounting for a large proportion of grade 3--4 hematologic toxicities and introducing a bias to higher treatment-related toxicities.

There was significant difference in anemia (*P*=0.040) and nausea/vomiting (*P*=0.003) between NACT + IMRT + CCRT group and NACT + IMRT group, while no significance was found in other toxicities between the two different arms.

RT efficacy
-----------

Tumor response in patients following RT is summarized in [Table 5](#t5-ott-12-1553){ref-type="table"}. No patient suffered with progressive disease.

For the primary tumor and the neck metastatic nodes, in the NACT + IMRT group, the RR was 91.7% (33/36), the CR rate was 66.7% (24/36), the PR rate was 25% (9/36), and 8.3% (3/36) of patients showed SD, while the RR was 93.3% (83/89), the CR rate was 71.9% (64/89), the PR rate was 21.4% (19/89), and 6.7% (6/89) of patients showed SD in the NACT + IMRT + CCRT group; in general, the RR was 92.8% (116/125), the CR rate was 70.4% (88/125), the PR rate was 22.4% (28/125), and 9 patients (7.2%) showed SD. Furthermore, compared with NACT + IMRT group, patients in NACT + IMRT + CCRT group did not show significantly better RR (93.3% vs 91.7%, *P*=1.00), CR rate (71.9% vs 66.7%, *P*=0.67), or PR rate (21.4% vs 25%, *P*=0.81).

For the primary tumor as well as the neck metastatic nodes, the RR, CR rate, PR rate, and SD rate were also exhibited; similarly, compared with NACT + IMRT group, patients in NACT + IMRT + CCRT group did not show significantly better results.

Efficacy and survival
---------------------

As shown in [Figure 1](#f1-ott-12-1553){ref-type="fig"}, in the NACT + IMRT group, patients' 3-year OS, LRFS, DMFS, and PFS rates were 89.4%, 91.7%, 83.3%, and 77.8%, respectively, while in the NACT + IMRT + CCRT group, patients' 3-year OS, LRFS, DMFS, and PFS rates were 88.5%, 94.4%, 82.0%, and 76.4%, respectively; moreover, compared with NACT + IMRT group, NACT + IMRT + CCRT group did not show significant improvements in 3-year OS rate (88.5% vs 89.4%, *P*=0.114), LRFS (94.4% vs 91.7%, *P*=0.124), DMFS (83.3% vs 82.0%, *P*=0.668), or PFS (77.8% vs 76.4%, *P*=0.475).

During the follow-up period, 8 patients (6.4%) suffered from locoregional recurrence and 19 patients (15.2%) developed distant metastasis, including 4 patients with both locoregional recurrence and distant metastasis. In total, 14 patients were dead, of whom 10 patients were dead from cancer progression, 2 patients were dead from dysphagia following RT, and 2 patients were dead from other diseases.

Prognostic factors
------------------

Univariate analysis with log-rank test and multivariate analysis with the Cox proportion hazards model were used to evaluate the independent potential prognostic factors for OS, DMFS, LRFS, and PFS as shown in [Tables 6](#t6-ott-12-1553){ref-type="table"} and [7](#t7-ott-12-1553){ref-type="table"}.

The potentially important prognostic factors considered in the modeling process were patient age (\<55 vs ≥55 years), gender (males vs females), T stage (T1--2 vs T3--4), N stage (N0--1 vs N2--3), use of CCRT (no vs yes), and GTVnx volume (cm^3^) (\<40 vs ≥40). In the multivariate analysis by prognostic factors, T classification (*P*=0.042) and N classification (*P*=0.021) were independent prognostic factors for DMFS.

Discussion
==========

CCRT has been regarded as standard therapeutic approach for locoregionally advanced NPC.[@b17-ott-12-1553] However, distant metastasis still frequently occurred and limited CCRT metastasis still frequently occurred and limited CCRT effect in the era of IMRT.[@b18-ott-12-1553] One previous study indicated that application of greatly decreased the risk of metastasis and prolonged OS time of stage IVb NPC patients treated with IMRT combined with RT or CCRT.[@b19-ott-12-1553] In current retrospective study, we set force to compare the stage III--VIb locoregionally advanced NPC patients' RR, the rates of PFS, RFS, MFS, and OS between NACT + IMRT group and NACT + IMRT + CCRT group.

Clinical trials 21 and 22 and meta-analyses 5 and 6 demonstrated that CCRT leads to improved prognosis in patients. The Intergroup Study 0099 first indicated that CDDP-based CRT improved patients' OS and event-free survival.[@b3-ott-12-1553] In the era of IMRT, however, none of local recurrence, distant metastasis rates, and OS after CDDP-based CCRT was improved since the replacement of conventional RT with IMRT.[@b10-ott-12-1553],[@b23-ott-12-1553],[@b24-ott-12-1553]

To reduce local recurrence and distant metastasis rates, novel CT regimens and optimized sequences for RT and CT delivery require further exploration. GEM was a novel nucleoside antimetabolite that inhibited DNA synthesis.[@b25-ott-12-1553] GEM-based chemotherapy was frequently used during treatment of metastatic NPC patients.[@b26-ott-12-1553] With different structure, NDP exhibited similar mechanism of action compared to CDDP.[@b27-ott-12-1553] Clinically, NDP showed to be more effective with lower frequency of toxicities in comparison with CDDP.[@b26-ott-12-1553] Our previous study investigated combination of NDP and GEM as neoadjuvant regimens in locoregionally advanced NPC patients. Unfortunately, their combination showed similar therapeutic effect compared with CBP + GEM or CDDP + GEM.[@b28-ott-12-1553] In patients who received CCRT or NACT followed by radiation, the use of NACT is increasing.[@b29-ott-12-1553] The addition of docetaxel, CDDP, and 5-fluorouracil induction chemotherapy to CCRT was beneficial for the survival of locally advanced NPC with nodal stage N2--3.[@b30-ott-12-1553] The above novel reports published in 2018 and 2017, respectively, showed the significance of addition of NACT in the treatment of locoregionally advanced NPC patients. However, there were also studies indicating the unnecessary addition of NACT; for instance, the induction chemotherapy followed by cetuximab RT is not superior to CCRT for head and neck carcinomas.[@b31-ott-12-1553] Meanwhile, no significant difference in OS or PFS was observed between IC+ volumetric modulated arc therapy group and IC/CCRT group in the treatment of stage II--IVB NPC patients, while more side effects were observed in the IC/CCRT arm.[@b32-ott-12-1553]

There was significant difference in anemia and nausea/vomiting between NACT + IMRT + CCRT group and NACT + IMRT group, while no significance was found in other toxicities between the two different arms. Patients who did not undergo CCRT showed a higher toxicity, on account of the positive effects of CCRT in the treatment of locoregionally advanced PC.[@b33-ott-12-1553] As for oropharyngeal mucositis, there was no significant difference between NACT + IMRT + CCRT group and NACT + IMRT group, which might due to the application of IMRT, consistent with a previous study indicating that texture analysis as a predictor of RT induced xerostomia in head and neck patients undergoing IMRT.[@b34-ott-12-1553]

In the current study, we sought to investigate whether NDP-based CCRT could improve prognosis of patients receiving NACT + IMRT. In terms of tumor response at the primary site and neck metastatic nodes following RT, RR in the NACT + IMRT + CCRT group was as high as93.3%, which was not significantly higher than that in the NACT + IMRT group (91.7%, *P*=1.000). The CR rate in NACT + IMRT + CCRT group was not superior to NACT + IMRT group (71.9% vs 66.70%, *P*=0.666). For patients in the NACT + IMRT + CCRT group, the 3-year OS, LRFS, DMFS, and PFS rates were 88.5%, 94.4%, 82.0%, and76.4%, respectively, which were not higher than those in the NACT + IMRT group that had an OS rate of 89.4% (*P*=0.114), DMFS rate of 83.3% (*P*=0.668), LRFS rate of 91.7% (*P*=0.124), and PFS rate of 77.8% (*P*=0.475). In summary, the results did not demonstrate any benefit for survival when NDP-based CCRT was added to IMRT following NACT regimen (NDP + GEM), which are in agreement with previous comparisons between IMRT with or without CT,[@b10-ott-12-1553],[@b22-ott-12-1553] while inconsistent with results from Ji et al.[@b11-ott-12-1553]

In the study by Cao et al,[@b10-ott-12-1553] 180 nonmetastatic T4 NPC patients, of whom 117 were treated by CCRT + IMRT and 63 were treated by IMRT, were retrospectively analyzed with a median follow-up time of 58.97 months. There was no statistically significant difference between CCRT + IMRT group and IMRT group regarding the 3/5-year local failure-free survival rates (89.2% vs 85.9%), regional failure-free survival rates (94.4% vs 94.4%), distant failure-free survival rates (79.9% vs 76.2%), or OS rates (78.9% vs 65.3%). In the study by Sun et al, 868 nonmetastatic NPC patients who were treated by IMRT with a median follow-up time of 50 months were retrospectively analyzed, of whom 217 received additional CCRT. The 5-year disease specific survival (78.4% vs 79.1%, *P*=0.340), LRFS (89.7% vs 89.1%, *P*=0.197), RRFS (96.6% vs 96.0%, *P*=0.280), DMFS (79.0% vs 80.8%, *P*=0.998), and PFS rates (70.5% vs 68.8%, *P*=0.480) were similar in IMRT + CCRT group vs IMRT group.[@b22-ott-12-1553]

In the study by Ji et al, 276 patients at stage II--IVb NPC with a median follow-up time of 33.8 months were analyzed. Compared with the IMRT group, addition of CCRT or NACT to IMRT is available to prolong patients' DFS (*P*=0.03) or RFS (*P*=0.01) and DFS (*P*=0.03), respectively, with no significant benefit in OS, MFS, RFS, or DFS.[@b11-ott-12-1553]

Based on the RR and 3-year OS rate in the NACT + IMRT group and NACT + IMRT + CCRT group, it appears that it is not necessary to add NDP-based CCRT to IMRT in patients with locoregionally advanced NPC who have received NACT regimen (NDP + GEM). Whereas there are several limitations in our retrospective study (1) the median follow-up period was insufficient; 2) the low numerosity of the cohort analyzed; 3) the proportion of patients who had a poorer prognosis at N2--3 was higher in NACT + IMRT + CCRT group; 4) the disequilibrium between the arms, as the proportion of patients with more significant health issues and a less advanced N stage was higher in the NACT + IMRT group; 5) 20 patients completed only one cycle of CCRT), it is unclear whether the number of cycles of CCRT influences the efficacy when combined with IMRT. Therefore, larger and better-designed studies with well-balanced prognostic factors with an adequate follow-up period were required to confirm the efficacy of CCRT + IMRT in locoregionally advanced NPC patients.

Conclusion
==========

No significant difference was observed in combined RR, CR, LRFS, DMFS, PFS, or OS rates between the two groups. Therefore, it might be unnecessary to add CCRT to IMRT following NACT in locoregionally advanced NPC in clinical.
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Abbreviations: CCRT, concurrent chemotherapy; IMRT, intensity modulated radiotherapy; NACT, neoadjuvant chemotherapy.](ott-12-1553Fig1){#f1-ott-12-1553}

###### 

Mean dose and maximum dose of crucial OAR

  Dose (Gy)                                 
  --------------------- ------------------- -------------------
                                            
  Brainstem             23.4 (18.3--27.5)   52.5 (49.5--56.8)
  Spinal cord           21.6 (14.9--29.8)   34.2 (28.9--42.6)
  Optic chiasm          30.5 (22.9--39.6)   45.2 (39.2--51.3)
  Left optic nerve      28.7 (20.3--39.8)   47.9 (40.1--55.3)
  Right optic nerve     32.2 (15.6--52.2)   50.2 (41.4--58.7)
  Left temporal lobe    20.5 (13.2--24.6)   58.4 (46.8--68.6)
  Right temporal lobe   21.2 (12.6--26.8)   60.7 (48.7--69.8)
  Left parotid gland    31.6 (24.3--36.5)   60.1 (50.2--68.5)
  Right parotid gland   30.2 (25.7--37.6)   58.5 (54.2--62.7)
  Left TMJ              34.5 (28.2--42.5)   47.4 (39.5--55.3)
  Right TMJ             35.7 (31.5--40.6)   45.2 (36.2--56.4)

**Abbreviations:** OAR, organ at risk; TMJ, temporomandibular joint

###### 

DVH statistics of targets

                      Average (range)                                                                      
  ------------------- -------------------- ------------------- -------------------- ---------------------- ---------------------
                                                                                                           
  Volume (cm^3^)      60.1 (18.2--156.4)   20.5 (6.5--55.9)    63.4 (14.7--144.3)   320.6 (212.6--598.7)   172.4 (78.3--305.7)
  Minimum dose (Gy)   62.1 (60.2--63.5)    61.8 (60.7--63.6)   50.4 (45.8--57.6)    48.7 (45.3--52.8)      40.7 (37.1--44.7)
  Maximum dose (Gy)   72.6 (71.5--73.2)    70.8 (69.2--73.1)   66.8 (63.7--69.2)    71.3 (69.8--73.6)      70.2 (67.8--73.4)
  Mean dose (Gy)      70.2 (68.2--72.2)    65.2 (63.4--68.4)   63.9 (61.7--68.7)    67.2 (64.5--69.6)      60.4 (58.4--62.6)

**Abbreviations:** DVH, dose--volume histogram; GTV, gross tumor volume; PTV, planning target volume; PTVnd, planning target volume of the metastatic nodes.

###### 

Characteristics of NPC patients treated with NACT + IMRT + CCRT vs NACT + IMRT

  Total (n=l25)                                      NACT + IMRT (n=36)   NACT + IMRT + CCRT (n=89)   
  -------------------------------------------------- -------------------- --------------------------- -------
                                                                                                      
  Age of diagnosis                                                                                    0.296
   \<55                                              16 (12.8)            46 (36.8)                   
   ≥55                                               20 (16.0)            43 (34.4)                   
  Gender                                                                                              0.429
   Female                                            13 (10.4)            29 (23.2)                   
   Male                                              23 (18.4)            60 (48.0)                   
  Smoking history                                                                                     0.162
   Never                                             22 (17.6)            44 (35.2)                   
   Ever                                              14 (11.2)            45 (36.0)                   
  Alcohol use                                                                                         0.454
   Never                                             23 (17.2)            58 (48.5)                   
   Ever                                              13 (6.1)             31 (28.3)                   
  Family history                                                                                      0.525
   No                                                30 (18.4)            57 (46.4)                   
   Yes                                               6 (10.4)             32 (24.8)                   
  WHO histology                                                                                       0.603
   II                                                6 (4.8)              15 (12.0)                   
   III                                               30 (24.0)            74 (59.2)                   
  AJcc stage                                                                                          0.319
   III                                               22 (17.6)            60 (48.0)                   
   IVA + IVB                                         14 (11.2)            29 (23.2)                   
  T stage                                                                                             0.276
   T1--2                                             11 (8.8)             34 (27.2)                   
   T3--4                                             25 (20.0)            55 (44.0)                   
  N stage                                                                                             0.153
   N0--1                                             17 (13.6)            29 (23.2)                   
   N2--3                                             19 (15.2)            60 (48.0)                   
  courses of NAcT                                                                                     
   I                                                 4 (3.2)              9 (7.2)                     0.548
   2--4[b](#tfn4-ott-12-1553){ref-type="table-fn"}   32 (25.6)            80 (60.0)                   

**Notes:**

Two-sided chi-squared test.

Only two patients receive four courses of NACT.

**Abbreviations:** AJCC, American Joint Committee on Cancer; CCRT, concurrent chemotherapy; IMRT, intensity modulated radiotherapy; NACT, neoadjuvant chemotherapy; NPC, nasopharyngeal carcinoma.

###### 

Treatment-related acute toxicities during NACT or RT in NPC patients treated with NACT + IMRT + CCRT vs NACT + IMRT

  During radiotherapy   NACT + IMRT (n=36)   NACT + IMRT + CCRT (n=89)   P-value                                                                      
  --------------------- -------------------- --------------------------- ------------ ----------- ------------ ------------ ------------ ------------ -------
                                                                                                                                                      
  **Hematologic**                                                                                                                                     
  Leukopenia            27 (75%)             7 (19.4%)                   20 (54.2%)   4 (11.1%)   59 (66.3%)   9 (10.1%)    55 (61.8%)   4 (4.5%)     0.362
  Neutropenia           15 (41.7%)           13 (36.1%)                  15 (41.7%)   3 (8.3%)    40 (44.9%)   25 (28.1%)   27 (30.3%)   6 (6.7%)     0.925
  Neutropenia fever     1 (2.8%)             1 (2.8%)                    0            0           2 (2.2%)     0            1 (1.1%)     0            N.A.
  Thrombocytopena       9 (25%)              7 (19.4%)                   12 (33.3%)   3 (8.3%)    18 (20.2%)   9 (10.1%)    31 (34.8%)   5 (5.6%)     0.702
  Anemia                23 (62.5%)           5 (13.9%)                   20 (54.2%)   3 (8.3%)    58 (65.2%)   1 (1.1%)     47 (52.8%)   4 (4.5%)     0.040
  **Nonhematologic**                                                                                                                                  
  Liver dysfunction     20 (54.2%)           5 (13.9%)                   6 (16.7%)    2 (5.6%)    49 (55.1%)   6 (6.7%)     15 (16.9%)   1 (1.1%)     0.394
  Kidney dysfunction    0                    0                           0            0           0            0            0            0            
  Diarrhea              1 (2.8%)             0                           0            0           2 (2.2%)     0            1 (1.1%)     0            N.A.
  Rash                  6 (16.7%)            0                           1 (2.8%)     0           11 (12.4%)   0            5 (5.6%)     0            N.A.
  Nausea/vomiting       18 (50.0%)           4 (11.1%)                   5 (13.9%)    1 (2.8%)    33 (37.1%)   6 (6.7%)     47 (52.8%)   14 (15.7%)   0.003
  Neurotoxicity         5 (13.9%)            0                           3 (8.3%)     0           7 (7.9%)     0            10 (10.7%)   0            N.A.
  Oropharyngeal         3 (8.3%)             0                           31 (86.1%)   6 (16.7%)   5 (5.6%)     0            72 (80.9%)   12 (13.5%)   N.A.
  mucositis                                                                                                                                           
  Hearing loss          1 (2.8%)             0                           1 (2.8%)     0           2 (2.2%)     0            1 (1.1%)     0            N.A.
  Radiodermatitis       --                   --                          6 (16.7%)    1 (2.8%)    --           --           14 (15.7%)   4 (4.5%)     N.A.

**Abbreviations:** CCRT, concurrent chemotherapy; IMRT, intensity modulated radiotherapy; N.A., not applicable; NACT, neoadjuvant chemotherapy; NPC, nasopharyngeal carcinoma; RT, radiotherapy.

###### 

Response of the primary site and the neck metastatic nodes in patients treated with NACT + IMRT + CCRT vs NACT + IMRT

                 Primary site                Neck                             Primary site + neck                             
  -------------- -------------- ------------ ------ ------------ ------------ --------------------- ------------ ------------ ------
                                                                                                                              
  RR (CR + PR)   34 (94.4%)     84 (94.4%)   0.68   35 (97.2%)   85 (95.5%)   1.00                  33 (91.7%)   83 (93.3%)   1.00
  CR             26 (72.2%)     67 (75.3%)   0.82   30 (83.3%)   70 (78.7%)   0.63                  24 (66.7%)   64 (71.9%)   0.67
  PR             8 (22.2%)      17 (19.1%)   0.81   5 (13.9%)    15 (16.8%)   0.79                  9 (25.0%)    19 (21.4%)   0.81
  SD             2 (5.6%)       5 (5.6%)     0.68   1 (2.8%)     4 (4.5%)     1.00                  3 (8.3%)     6 (6.7%)     1.00
  PD             0              0            \-     0            0            \-                    0            0            --

**Note:**

Two-sided chi-squared test.

**Abbreviations:** NACT, neoadjuvant chemotherapy; IMRT, intensity modulated radiotherapy; CCRT, concurrent chemotherapy; RR, response rate; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease.

###### 

Multivariate analysis of prognostic factors

  Items                  3-year OS   3-year LRFS                                         3-year DMFS   3-year PFS                                                                                                            
  ---------------------- ----------- --------------------------------------------------- ------------- --------------------------------------------------- ------ --------------------------------------------------- ------ ---------------------------------------------------
                                                                                                                                                                                                                             
  Age (years)                        0.872                                                             0.484                                                      0.538                                                      0.347
   \<55                  89.2                                                            94.7                                                              83.4                                                       77.2   
   ≥55                   87.6                                                            92.8                                                              81.2                                                       75.4   
  Gender                             0.596                                                             0.287                                                      0.773                                                      0.457
   Male                  89.3                                                            93.9                                                              83.8                                                       77.5   
   Female                87.7                                                            93.2                                                              81.2                                                       75.8   
  T stage                            0.092                                                             0.005[\*](#tfn9-ott-12-1553){ref-type="table-fn"}          0.574                                                      0.060
   T1-2                  89.8                                                            94.8                                                              82.1                                                       77.9   
   T3-4                  87.5                                                            92.1                                                              82.8                                                       75.8   
  N stage                            0.002[\*](#tfn9-ott-12-1553){ref-type="table-fn"}                 0.001[\*](#tfn9-ott-12-1553){ref-type="table-fn"}          0.032[\*](#tfn9-ott-12-1553){ref-type="table-fn"}          0.001[\*](#tfn9-ott-12-1553){ref-type="table-fn"}
   N0-1                  92.4                                                            95.6                                                              84.7                                                       78.8   
   N2-3                  83.5                                                            91.8                                                              80.2                                                       74.6   
  Smoking                            0.691                                                             0.554                                                      0.428                                                      0.337
   Never                 89.6                                                            91.2                                                              83.5                                                       77.8   
   Ever                  86.8                                                            95.4                                                              81.6                                                       76.0   
  Alcohol use                        0.769                                                             0.443                                                      0.352                                                      0.287
   Never                 88.2                                                            92.8                                                              81.4                                                       75.7   
   Ever                  89.4                                                            94.5                                                              83.6                                                       77.9   
  Use of CCRT                        0.114                                                             0.124                                                      0.668                                                      0.475
   No                    89.4                                                            91.7                                                              83.3                                                       77.8   
   Yes                   88.5                                                            94.4                                                              82.0                                                       76.1   
  GTVnx volume (cm^3^)               0.438                                                             0.473                                                      0.040[\*](#tfn9-ott-12-1553){ref-type="table-fn"}          0.145
   \<40                  89.1                                                            93.2                                                              84.8                                                       77.5   
   ≥40                   87.7                                                            93.9                                                              80.1                                                       76.2   

**Note:**

*P*\<0.05.

**Abbreviations:** CCRT, concurrent chemoradiotherapy; DMFS, distant metastasis-free survival; LRFS, local relapse-free survival; OS, overall survival; PFS, progression-free survival.

###### 

Multivariate analysis of prognostic factors

  Factors                3-year OS   3-year LRFS   3-year DMFS                                          3-year PFS
  ---------------------- ----------- ------------- ---------------------------------------------------- ------------
                                                                                                        
  Age (years)                                                                                           
   \<55 vs ≥55           0.572       0.483         0.396                                                0.424
  Gender                                                                                                
   Female vs male        0.426       0.537         0.389                                                0.692
  T stage                                                                                               
   T1-2 vs T3-4          0.224       0.186         0.042[\*](#tfn11-ott-12-1553){ref-type="table-fn"}   0.221
  N stage                                                                                               
   N0-1 vs N2-3          0.337       0.281         0.021[\*](#tfn11-ott-12-1553){ref-type="table-fn"}   0.342
  Use of CCRT                                                                                           
   No vs yes             0.398       0.592         0.424                                                0.482
  GTVnx volume (cm^3^)                                                                                  
   \<40 vs ≥40           0.192       0.342         0.112                                                0.173

**Note:**

P\<0.05.

**Abbreviations:** CCRT, concurrent chemoradiotherapy; DMFS, distant metastasis-free survival; LRFS, local relapse-free survival; OS, overall survival; PFS, progression-free survival.
